1198-P: The M-EASE Studies: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM)

BRUCE A PERKINS; NIMA SOLEYMANLOU; JULIO ROSENSTOCK; JAY S SKYLER; LORI M LAFFEL; KARL-HEINZ LIESENFELD; DIETMAR NEUBACHER; MATTHEW RIGGS; CURTIS K JOHNSTON; RENA J EUDY-BYRNE; AHMED ELMOKADEM; JYOTHIS GEORGE; JAN MARQUARD; VALERIE C NOCK

doi:10.2337/db19-1198-P

Back

1198-P: The M-EASE Studies: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM)

Journal article

Peer reviewed

1198-P: The M-EASE Studies: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM)

BRUCE A PERKINS, NIMA SOLEYMANLOU, JULIO ROSENSTOCK, JAY S SKYLER, LORI M LAFFEL, KARL-HEINZ LIESENFELD, DIETMAR NEUBACHER, MATTHEW RIGGS, CURTIS K JOHNSTON, RENA J EUDY-BYRNE, …

Diabetes (New York, N.Y.), Vol.68(Supplement 1), p.1198

2019-06

DOI: https://doi.org/10.2337/db19-1198-P

Metrics

9 Record Views

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: 1198-P: The M-EASE Studies: A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM)
Creators: BRUCE A PERKINS
NIMA SOLEYMANLOU
JULIO ROSENSTOCK
JAY S SKYLER
LORI M LAFFEL
KARL-HEINZ LIESENFELD
DIETMAR NEUBACHER
MATTHEW RIGGS
CURTIS K JOHNSTON
RENA J EUDY-BYRNE
AHMED ELMOKADEM
JYOTHIS GEORGE
JAN MARQUARD
VALERIE C NOCK
Publication Details: Diabetes (New York, N.Y.), Vol.68(Supplement 1), p.1198
Academic Unit: Miller School of Medicine; Diabetes Research Institute (DRI)
Language: English
Resource Type: Journal article
Record Identifier: 991031600120102976